Get in touch +44 (0)141 255 1640 | firstname.lastname@example.org
You are here:Home1/Blog2/Quantification of Dual LAG-3 and CD3 IHC-stained T Cells in Clinical Tumor...
Quantification of Dual LAG-3 and CD3 IHC-stained T Cells in Clinical Tumor Tissue using Image Analysis
The characterisation of immune cells within the tumor microenvironment and their potential impact on cancer treatment and prognosis has been the subject of intense investigation over recent years. Non-small cell lung cancer (NSCLC) patients have impaired immune responses, where the expression of inhibitory checkpoint molecules on T cells may lead to reduced immune cell activity.
One implication has been the engagement of LAG-3 inhibiting T cell proliferation, resulting in T cell suppression and poor prognosis. Consequently, LAG-3 immune checkpoint molecules are being investigated as a potential oncology target for modulating T cell responses in NSCLC disease.
One of the challenges in characterising LAG-3 within the tumour microenvironment is identifying the population of T cells expressing LAG-3 over other LAG-3 positive cells including B cells, NK cells, macrophages and dendritic cells.
OracleBio has been collaborating with one of our histology CRO partners, Indivumed GmbH, to develop a dual IHC staining assay which, when combined with quantitative analysis for specific identification and evaluation of LAG-3 positive T cells within clinical tumor samples.
Figure 1. (A) Magnified tissue section with IHC staining showing CD3 single positive cells (purple), LAG-3 single positive cells (brown), LAG-3/CD3 dual positive (purple/brown) and nuclear counterstain (blue). (B) Deconvoluted image showing CD3 positive staining. (C) Deconvoluted image showing LAG3 positive staining. (D) Image analysis overlay, where cytoplasmic borders for CD3 positive cell (light purple), LAG-3 positive (brown), LAG-3+/CD3+ dual positive (purple/brown) and nuclei (blue).
To exemplify the utilisation of this approach, a clinical sample of NSCLC tissue was dual IHC stained for LAG-3 and CD3 and analysed to quantify the number of LAG-3 positive T cells and associations with surrounding tumour microenvironment.
The approach described above highlights the application of high quality dual IHC staining with whole slide image analysis to characterise exemplar immune cells, or any specified dual stained immune cell combinations, in order to evaluate cell relationships within the tumour microenvironment.
For more information on how OracleBio can support evaluation of oncology immunotherapy mechanistic read-outs please contact us.
To keep up to date with all OracleBio news and blogs, please follow us on LinkedIn by clicking:
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Google Analytics Cookies
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
Other external services
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them: